For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Argireline
Skin & Hairpreclinical

Argireline

Acetyl Hexapeptide-8
Skin & Hair
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Skin & Hair
Evidence grade
D
PubMed records
45
Female-tagged
7
Sex-analysis
0
CAS
—
D
Evidence grade D, Preclinical / animal evidence only across 45 indexed studies. No human trial data. How grades work →
Female evidence: None
Argireline: of 45 PubMed records, 7 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Argireline is an acetylated hexapeptide, a short synthetic six-amino-acid sequence, widely used as a research material in cosmetic-dermatology and cell-biology studies. Its small, stabilized structure gives it a research-friendly profile for laboratory work on defined signaling components.

In preclinical and in-vitro models Argireline has been studied for its relationship to the SNARE complex, the protein machinery involved in vesicle fusion and neurotransmitter release. Researchers examining SNARE-mediated signaling have used the peptide as a tool to characterize how modulation of this complex behaves in cell-based systems, which is why it is a common reference compound in cosmetic-science research.

What makes Argireline a notable entry for a skin-and-cell research catalog is the relative specificity of its studied mechanism at the SNARE complex. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Argireline (acetyl hexapeptide-8) is a topical cosmetic peptide marketed to soften expression lines. Its evidence is mostly small formulation and skin-permeability studies rather than rigorous clinical trials, and no analysis is broken out for female-specific physiology despite a predominantly female user base.

Evidence in women

Menstrual cycle
Unstudied
No study relates topical argireline to menstrual cycle phase.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data for cosmetic use.
Hormonal interactions
Unstudied
No data on hormonal interactions.
Perimenopause & menopause
Unstudied
Skin ageing accelerates around menopause, but no menopause-specific argireline data exist.
Sex differences
Unstudied
Cosmetic studies did not analyze outcomes by sex.

Mechanism

Modeled on SNAP-25, it is proposed to modestly reduce neurotransmitter release involved in facial muscle contraction when applied topically.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Used topically (commonly ~5–10% in cosmetic formulations); no systemic dose and limited clinical efficacy data.
Routestopical
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

topical use; systemic effects not characterizedlocal irritation (uncommon)

Argireline reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Argireline

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Argireline's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Argireline?

Argireline, also known as Acetyl Hexapeptide-8, is a research compound in our skin hair category. Argireline (acetyl hexapeptide-8) is a topical cosmetic peptide marketed to soften expression lines.

Is Argireline studied in women?

Argireline: of 45 PubMed records, 7 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for Argireline is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has Argireline been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data for cosmetic use. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Argireline have, and why?

Argireline carries evidence grade D. Preclinical / animal evidence only across 45 indexed studies. No human trial data.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Argireline?

No. A female-specific dose for Argireline is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Argireline administered in research?

In the published literature, Argireline is administered via topical. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Argireline?

Effects reported in the research literature include topical use; systemic effects not characterized, local irritation (uncommon). Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Argireline be stored and handled?

Argireline sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Argireline for research?

Argireline is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Argireline isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

40565185 · 39233460

Related peptides

GHK-CuC
GHK-Cu: of 81 PubMed records, 0 are tagged as including female subjects and 0 carry a sex-analysis tag.
GLOW - GHK-Cu (50mg) / BPC-157 (10mg) / TB500·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
KLOW - GHK-Cu (50mg) / KPV (10mg) / BPC-157 (10mg) / TB500·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
MatrixylD
Matrixyl: of 30 PubMed records, 5 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.